The researchers said their findings could help classify BRCA1 variants, particularly one whose impact on cancer risk is currently not clear.
The team also elucidated well-established and controversial non-BRCA predisposition genes associated with breast or ovarian cancer.
Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.
The FDA granted the assay's status based on its ability to detect both ovarian and pancreatic cancer in asymptomatic individuals over the age of 65.
Researchers led by MD Anderson’s Karen Lu want to know the most efficient genetic counseling strategy as more people are getting screened for cancer risk genes.
A team of researchers in Japan used a noninvasive prenatal testing platform to detect copy number alterations in about 20 percent of gynecological cancers they tested.
The team will use a S$1.5 million grant to develop a database of mutations that cause hereditary breast and gynecological cancers in Asian women.
DeCode's new offering adds to an ongoing controversy over whether people in the island country have a right to know if they are at increased risk for disease.
Researchers used CRISPR-Cas9 screening assays in mouse and human cells to track down point mutations in the PARP1 gene that boost resistance to PARP inhibitor drugs.
Researchers find that a personalized ovarian cancer vaccine appears safe, the Los Angeles Times reports.
Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.
The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.
Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.
In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.